High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial†

Cited by (318)

Items 301–318 of 318

1. Graft injury and re-transplantation in liver transplant patients with COVID-19
   Alexander Clevewood Ng · 2021 · Journal of Liver Transplantation
2. NON-ALCOHOLIC FATTY LIVER DISEASE IN DIABETIC AND NONDIABETIC PATIENTS
   2021 · International Journal of Biology Pharmacy and Allied Sciences
3. E-Manuscript Article Summaries
   Current Oncology Editorial Office · 2011 · Current Oncology
4. Foie métabolique
   Maud Lemoine, Lawrence Serfaty · 2011 · EMC - Hépatologie
5. Drugs and Mechanisms Related to the Treatment of Nonalcoholic Fatty Liver Disease
   钊 牟 · 2021 · Advances in Clinical Medicine
6. BAR502/fibrate conjugates: synthesis, biological evaluation and metabolic profile
   Claudia Finamore, Simona De Marino, Chiara Cassiano, Giuliano Napolitano, Pasquale Rapacciuolo, Silvia Marchianò, Michele Biagioli, Rosalinda Roselli, Cristina Di Giorgio, Carmen Festa et al. · 2024 · Frontiers in Chemistry
7. Ursodeoxycholic acid in hepatobiliary diseases
   Hyuk Kim, Jeong‐Ju Yoo · 2024 · Journal of Korean Medical Association
8. Metabolic dysfunction associated steatotic liver disease in lean patients. Diagnostic and treatment challenges
   E. E. Zabotina, Yu.A. Khabarova, N. Y. Stukova · 2025 · Experimental and Clinical Gastroenterology
9. Liver and diabetes
   Eleni Rebelos, Dimitris C. Kounatidis · 2025 · Elsevier eBooks
10. Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction–associated steatotic liver disease and its progression to hepatocellular carcinoma
    Thomai Kouti, Panayiota Christodoulou, Stephanos Christodoulides, Foula Protopapa, Charalambos Michaeloudes, Paraskevi A. Farazi · 2026 · Frontiers in Nutrition
11. Standard-Dose Ursodeoxycholic Acid Improves Biochemical Liver Function and Fibrosis in Chronic Liver Disease: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Young Woon Chang, Yong Kyun Cho, Young Seok Kim, Sung Eun Kim, Gab Jin Cheon, Ji Hoon Kim, Hyun Jin Yang, Won Kim, Sang Bong Ahn, Eileen Laureal Yoon et al. · 2026 · Journal of Korean Medical Science
12. Marqueurs diagnostiques et pronostiques de la stéatohépatite métabolique
    Audrey Coilly · 2019
13. From chemical composition to clinical application: the value of bile-based traditional Chinese medicines in the treatment of liver diseases
    Xue Liang, Yuehui Liang, Siqi Liu, Lin Yu, Yunxiao Liang, Lei Zhou · 2026 · Frontiers in Pharmacology
14. Dysregulation of the bile acid signaling network in non-alcoholic fatty liver disease: Mechanisms and a new paradigm of precision network pharmacology
    Haoze Yang, Xuyao Zhang, Dan Zhou, Jing Zou, Lei Xu, Miaona Chen, Siyu Zhao, Jiaxuan Dai, Xiaoming Wang, Xi Du et al. · 2026 · Biochemical Pharmacology
15. Metabolic dysfunction–associated steatotic liver disease assessment and management: Clinical practice guidance from the Canadian Association for the Study of the Liver
    Mohit Kehar, Alnoor S. Ramji, Mark Swain, Alexander G. Singer, NOAH IVERS, Wendy Schaufert, Michael Betel, Kaberi Dasgupta, Giada Sebastiani, Keyur Patel · 2026 · Canadian Liver Journal
16. A review of non-alcoholic fatty liver disease with a special focus on evidence-based Unani therapeutic approaches: a scoping review
    Nida Mehraj, Atiba Jan, Pawan Kumar, Rameesa Rashid · 2026 · Journal of Complementary and Integrative Medicine
17. The association of primary biliary cholangitis with metabolic syndrome and metabolic dysfunction-associated steatotic liver disease
    Maya Mahmoud, Mohamed Awali, Wing-Kin Syn, Kamran Qureshi · 2026 · Exploration of Digestive Diseases
18. Pharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates
    Majid Mufaqam Syed‐Abdul · 2026 · Expert Opinion on Pharmacotherapy